STK11 and cancer: ,53,54 Regarding KRAS, STK11 mutation is significantly enriched in KRAS G12C-mutated tumors compared to KRAS non-G12C-mutated tumors (20.59% vs. 5.95%, [OR] = 4.10) across all cancer types, indicating their potential relationship.4